Showing 1,581 - 1,600 results of 47,810 for search '(( 50 ((nn decrease) OR (a decrease)) ) OR ( 5 ((fold decrease) OR (mean decrease)) ))', query time: 0.71s Refine Results
  1. 1581
  2. 1582
  3. 1583
  4. 1584

    Spatial stability is decreased in APP/PS1 mice in both dCA1 and vCA1. by Udaysankar Chockanathan (18510288)

    Published 2024
    “…<p>(A) In dCA1, stability score was significantly decreased in APP/PS1 mice relative to C57BL/6 mice (mean ± std: C57BL/6 = -0.009 ± 0.292, APP/PS1 = -0.1845 ± 0.256, p < 10<sup>−6</sup>, two-sided Wilcoxon rank-sum test, n<sub>C57BL/6</sub> = 295 units from 5 recording sessions, n<sub>APP/PS1</sub> = 167 units from 4 recording sessions). …”
  5. 1585
  6. 1586

    <i>Zip88E</i><sup><i>Δ/Δ</i></sup> larvae have decreased <i>MtnB</i>:<i>EYFP</i> expression. by Christopher D. Richards (4246669)

    Published 2017
    “…Band intensity for <i>Zip88E</i><sup><i>Δ/Δ</i></sup> larvae was calculated relative to controls and averaged over multiple western blots (values are represented as the mean ± SD, N ≥ 3). C) There is an approximate 5 fold decrease in <i>MtnB</i>:<i>EYFP</i> expression in <i>Zip88E</i><sup><i>Δ/Δ</i></sup> larvae compared to controls when raised on basal media. …”
  7. 1587
  8. 1588
  9. 1589
  10. 1590
  11. 1591
  12. 1592
  13. 1593

    Decreased self-renewal capacity associated with senescence was prevented in human MSCs following treatment with Ki16425, an LPA<sub>1</sub>/LPA<sub>3</sub> antagonist. by Masahiko Kanehira (183764)

    Published 2012
    “…Human MSCs at passage 2 were cultured in the presence or absence of Ki16425 for the indicated days prior to cell lysis. Fold-change represents decrease in band intensity of Ki16425 treatment for 18 days compared with a control treatment for the same period of time. …”
  14. 1594
  15. 1595
  16. 1596
  17. 1597
  18. 1598
  19. 1599
  20. 1600

    List of Included studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”